Preston Tse, Jiajun Yan, Yang Liu, Erin Jamula, Nancy Heddle, Renée Bazin, Nancy Robitaille, Richard Cook, Alexis Turgeon, Dean Fergusson, Marshall Glesby, Kent Cadogan Loftsgard, Melissa Cushing, Michaël Chassé, Nick Daneman, Andrés Finzi, Bruce Sachais, Philippe Bégin, Jeannie Callum, Donald M Arnold, Feng Xie
BACKGROUND: The CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) trial was a multicenter randomized controlled trial assessing convalescent plasma in hospitalized COVID-19 patients. This study evaluates the cost-effectiveness of convalescent plasma and its impact on quality-of-life to provide insight into its potential as an alternative treatment in resource-constrained settings. METHODS: Individual patient data on health outcomes and resource utilization from the CONCOR-1 trial were used to conduct the analysis from the Canadian public payer's perspective with a time horizon of 30 days post-randomization...
March 21, 2024: Transfusion